Cite
MLA Citation
Panagiotis A Konstantinopoulos et al.. “Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.” Lancet oncology, vol. 20, no. 4, 2019, pp. 570–580. http://access.bl.uk/ark:/81055/vdc_100079603683.0x00001c